19 provinces including Hubei, Hebei and other provinces began to purchase Chinese patent medicines in volume, and the tide of price cuts struck again

 Procurement of proprietary Chinese medicines in 19 provinces has officially started! Recently, Hubei Province Pharmaceutical Price and Bidding Procurement Management issued the "Announcement of Centralized Procurement of Chinese Patent Medicine Interprovincial Alliance (No.
1)".
The announcement pointed out that this procurement alliance is composed of 19 provinces and regions including Hubei, Hebei, and Shanxi.
The scope of bulk procurement of Chinese patent medicines includes all public medical institutions in the alliance area, and designated social medical institutions and designated pharmacies by medical insurance are encouraged to participate in accordance with the relevant regulations of the alliance area
.
The announcement of this announcement also means that the prelude to the collection of proprietary Chinese medicines has begun
.
The procurement varieties in the document select 76 intermediate-grade drugs produced by many companies with large clinical use, high procurement amount
.
In principle, the procurement cycle is 2 years, calculated from the actual implementation date of the selected results
.
The purchase agreement is signed every year during the purchase cycle.
If the agreed purchase amount of the year is completed in advance during the purchase cycle, the selected companies will still supply the selected companies at the selected price until the end of the purchase cycle
.
It is understood that, in addition to the 19 provinces announced by Hubei Province to purchase Chinese patent medicines in bulk, many places have recently started the centralized procurement of Chinese patent medicines
.
For example, on September 14, the Guangdong Provincial Drug Trading Center issued an opinion on the solicitation of the "Guangdong Union Qingkailing and other 58 drug groups' procurement documents (draft for comments)"; on September 17, the Jilin Provincial Public Resources Trading Center also released A notice on the formal negotiation of the third batch of Chinese patent medicines for the centralized procurement of medicines by medical institutions in Jilin Province in 2021
.
In addition, on September 15th, the National Medical Security Administration stated that the "Announcement on Ending the Pilot Work of TCM Formula Granules" clearly stated that if the varieties of TCM decoction pieces have been included in the scope of medical insurance payment, each provincial medical insurance department can comprehensively consider clinical needs and fund payment Factors such as capacity and price, after expert review, will include the TCM formula granules corresponding to TCM decoction pieces into the payment scope, and refer to Type B management
.
With the start of the centralized procurement of Chinese patent medicines in various places, the big game of reducing the price of Chinese patent medicines will also be "laid
.
" According to the industry, from the previous pilots for centralized procurement of Chinese patent medicines in Qinghai Province, Jinhua, Zhejiang, Puyang, Henan and other regions, although the types of centralized procurement in the pilots are basically those with high demand and high amounts, the price reductions are basically the same.
Looking at below 50%, it is expected that the price of Chinese patent medicines produced by the country may also be reduced by about 50%.

.
In addition, some people said that in each round of volume procurement, whether it is centralized procurement of Chinese patent medicines or centralized procurement of chemical medicines, whether it is national or provincial procurement, based on certain varieties and enterprises, the setting of rules serves to exchange prices by volume.
, The principle of large quantity and low price, which determines that the setting of the rules will focus on the two dimensions of full competition, guaranteeing price reduction, and reasonable allocation of guaranteed quantity
.
"It's not difficult to see that if you want exclusive products to get more increments, you must implement price reductions on a larger scale
.
" The trend of collecting Chinese patent medicines has come, but the collecting of Chinese patent medicines is only the first step.
The industry said, If the centralized procurement of traditional Chinese medicine is to be fully deployed in the future, clear industry standards must be established
.
In terms of quality, the establishment of a standardization system for traditional Chinese medicine should be promoted to form group standards, local standards, industry standards, national standards, international standards, and a multi-level, multi-dimensional, and whole-process quality control system covering medicinal materials, intermediates, and finished products
.
In terms of curative effect, it is necessary to emphasize the clinical value-oriented and establish an evidence-based medical evaluation system that conforms to the characteristics of Chinese medicine, so as to achieve data-based, data-based evidence, and evidence-based evaluation of traditional Chinese medicine
.
The centralized procurement of Chinese patent medicines has already begun, and in the face of the advancement of centralized procurement, a batch of proprietary Chinese medicine companies may be eliminated in the future
.
Therefore, under the pressure of centralized procurement, relevant companies need to focus more on the research and development of innovative Chinese medicines with relatively high academic content, and strive to introduce more innovative products with characteristics to benefit more patients
.
In this regard, the relevant pharmaceutical companies stated that they are studying the plan based on their own product conditions, and will draw up corresponding plans based on the combination of product grouping, declared volume, and manufacturer competition
.